Chengdu Shengnuo Biotech participated in the 7th National Polypeptide Drug R&D and Large-scale Production Frontier Technology Academic Exchange Conference
In November, when the chill is first revealed, Hainan Province, the southernmost province of the motherland, is as brilliant as summer. On the 11th, with the breeze of the sea, the 7th National Polypeptide Drug R&D and Large-scale Production Frontier Technology Academic Exchange Conference opened grandly in Sanya, Hainan Province.
The conference invited domestic and foreign industry experts and senior leaders of well-known domestic peptide companies to discuss the latest trends in peptide drugs, the registration of the internationalization of the peptide industry and the registration of international R&D, new technologies and quality control of peptide drugs, and in-depth exchanges on the development of peptide drug R&D and large-scale production. trend.
The National Polypeptide Drug R&D and Large-scale Production Frontier Technology Academic Exchange Conference, sponsored by Hainan Jianbang Pharmaceutical Technology Co., Ltd. and China Polypeptide Industry Alliance, aims to serve the high-level technical exchanges among peers in the field of peptide drugs, increase opportunities for cooperation, and deepen friendship. comminicate. After 6 sessions, the conference has gradually become a cutting-edge exchange meeting for experts and colleagues in the field of peptide drugs.
Wen Yongjun, chairman of Chengdu Shengnuo Biotechnology, delivered a speech at the exchange meeting
This academic exchange meeting, as always, attracted the participation of many professionals in the field of peptide drugs at home and abroad. The academic atmosphere of the exchange meeting was strong. Representatives of various companies expressed their opinions on the current development of the peptide industry and actively published relevant research and questions on industrial development and technical difficulties. Wen Yongjun, chairman of Chengdu Shengnuo Biotechnology, shared the current status of the development of innovative peptide drugs at home and abroad in combination with the current global peptide industry issues. In addition, representatives of well-known domestic peptide companies, such as Hainan Jianbang, Sinopeptide Biochemical, and Hainan Shuangcheng, have also made academic reports related to the diversified peptide industry.
Chengdu Shengnuo Biotech participated in the 7th National Polypeptide Drug R&D and Large-scale Production Frontier Technology Academic Exchange Conference
This academic conference provided a communication platform for enhancing the deeper understanding of peptide companies at home and abroad, promoted technological exchanges among peers, and played a positive role in promoting cutting-edge technological innovation cooperation and industrial development.
As a domestic first-class enterprise specialized in the large-scale production of peptide drugs, Chengdu Shengnuo Biotech has always been based on the large-scale production and sales of raw materials, and is committed to building its brand with innovative peptide drug pharmaceutical research services and peptide product customized production services. At the same time, Sinobio is also trying to advance into the preparation market, through more diversified business integration, to give play to the company’s advantages in the field of peptides, and promote the healthy development of the domestic peptide industry.